Flexible funding needed?
Ad-hoc grants
This channel allows EB Resnet and its potential grantholders to remain flexible and to respond in a timely manner to opportunities that arise, such as co-funding options, immediate need for funds, novel project ideas, or proof-of-concept projects.
Academic researchers, clinicians and also industry may approach EB Resnet outside the scheduled research-proposal calls if there is an urgent need or a co-funding opportunity arises. This funding channel is only available while no research grant call is open. For example, an international or national funding scheme, a company or another patient group may offer funding schemes that also invite co-funding. Proposals more appropriate to scheduled research grant calls or industry co-funding, will be redirected.
Project scope 'Ad-hoc grants'
- Fundamental to clinical research projects in EB
- Quick funding/co-funding to respond to an opportunity arising in fundamental to preclinical research or a proof-of-concept project in EB
- Lead applicant: researchers, clinicians, and/or industry partners (cooperation with industry welcome and possible)
- Project duration: up to 12 months
- Funding: up to EUR 100,000.00 p.a.
Closed Calls 2022
This year's All Priorities Call closed on 06 September 2022. Full details including deadlines and scope are displayed under Closed Call 'AP Call 2022'.
In addition, a Special Ad-hoc Call 2022 focussing on Proof-of-Concept Proposals on Drug Repurposing for EB closed on 06 September 2022 too. Full details including deadlines and scope are displayed under Closed Call 'Special Ad-hoc Call 2022'.
The results of the All Priorities Call 2021 can be found in the overview table for 2021.
Application process Ad-hoc grants
The application process has two steps. Informal application is done via a letter of interest (LOI) to office@eb-researchnetwork.org.
Please bear in mind that this funding channel is only available while no research grant is open - check under Research grants.
You will be informed whether your project fits into our funding scheme and if so, sent a link to our Grant Management online Application form.
Ad-hoc grants
| Project lead | Organisation/ Institute | Duration | Research area | EB-type | Funder(s) |
| Ad-hoc 2023/1 | Prof John Connelly | Queen Mary University of London, UK | 9 months | EB genetics, epigenetics & biology | EBS | DEBRA Austria |
| Ad-hoc 2021/2 | Dr. Ulrich Koller | EB House Austria, Salzburg, Austria | 3 years | Molecular therapy & cellular therapy | RDEB | DEBRA Austria |
| Ad-hoc 2021/1 | Dr. Gudrun Salamon | Siegmund Freud University Vienna | 2 years | Psychology | all | DEBRA Austria |
| Ad-hoc 2020/2 | Dr. Mattew Caley | Queen Mary University London, UK | 2 years | Small molecules | Junctional | DEBRA Austria LifeArc Philantrophic Fund (UK) |
| Ad-hoc 2020/1 | Prof. Dennis Roop, Dr. Ganna Bilousova | University of Colorado, Denver, USA | 3 years | Preclinical | Simplex
| DEBRA Austria Vlinderkindje (B) |
| Ad-hoc 2019/1 | Dr. Thomas Magin | University of Leipzig, Germany | 1 year | Fever in EB | Simplex
| DEBRA Austria Tove Bruce (Sweden) |
| Ad-hoc 2019/2 | DDr. Gudrun Salamon | Sigmund Freud University, Austria | 18 months +1 months Extension | Quality of life, Psychology | Simplex, Dystrophic, Junctional | DEBRA Austria |
| Ad-hoc 2017/1 | Dr. Alexander Nyström, Dr. Leena Bruckner-Tuderman | University of Freiburg - Medical Center, Departement of Dermatology, Germany | 1 year | Preclinical, fibrosis | Dystrophic | DEBRA Austria |
| Ad-hoc 2016/1 | Prof. Dennis Roop | University of Colorado, Denver, USA | 2 years | Preclinical | Simplex | DEBRA Austria Vlinderkindje (B) |
